OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
+21.36%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$456M
AUM Growth
+$456M
(-10%)
Cap. Flow
-$144M
Cap. Flow
% of AUM
-31.52%
Top 10 Holdings %
Top 10 Hldgs %
60.57%
Holding
36
New
2
Increased
7
Reduced
13
Closed
6
Top Buys
| 1 |
ARS Pharmaceuticals
SPRY
|
$12.7M |
| 2 |
Kymera Therapeutics
KYMR
|
$11.6M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$11.3M |
| 4 |
DBVT
DBV Technologies
DBVT
|
$9.31M |
| 5 |
Taysha Gene Therapies
TSHA
|
$4.37M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Dianthus Therapeutics
DNTH
$759M
| $43.6M | 9.57% | 2,341,667 | – | – |
|
2
ArriVent BioPharma
AVBP
$776M
| $42.4M | 9.3% | 1,946,054 -113,333 | -6% | -$2.47M |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $31.9M | 7% | 337,000 +119,736 | +55% | +$11.3M |
|
|
4
Taysha Gene Therapies
TSHA
$797M
| $29.1M | 6.38% | 12,592,500 +1,892,500 | +18% | +$4.37M |
|
|
5
ARS Pharmaceuticals
SPRY
$1.15B
| $23.6M | 5.17% | 1,350,000 +725,000 | +116% | +$12.7M |
|
6
Gossamer Bio
GOSS
$562M
| $22.6M | 4.95% | 18,350,000 | – | – |
|
7
Ocular Therapeutix
OCUL
$2.12B
| $22.5M | 4.94% | 2,425,000 | – | – |
|
8
Merus
MRUS
$4.98B
| $20.5M | 4.49% | 389,000 +81,000 | +26% | +$4.26M |
|
9
Trevi Therapeutics
TRVI
$883M
| $20.1M | 4.41% | 3,672,000 +350,000 | +11% | +$1.91M |
|
10
Cogent Biosciences
COGT
$1.69B
| $19.8M | 4.35% | 2,763,000 | – | – |
|
|
ATYR
11
aTyr Pharma
ATYR
$527M
| $19.4M | 4.25% | 3,820,000 +268,000 | +8% | +$1.36M |
|
12
Apellis Pharmaceuticals
APLS
$3.48B
| $15.6M | 3.43% | 903,500 -1,190,500 | -57% | -$20.6M |
|
13
Nuvation Bio
NUVB
$1.02B
| $15M | 3.29% | 7,691,334 -208,666 | -3% | -$407K |
|
14
Tourmaline Bio
TRML
$601M
| $14.5M | 3.18% | 905,000 | – | – |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $14.4M | 3.16% | 1,273,333 -96,667 | -7% | -$1.09M |
|
16
MindMed
MNMD
$676M
| $13.8M | 3.03% | 2,130,000 -888,000 | -29% | -$5.76M |
|
|
CNTA
17
Centessa Pharmaceuticals
CNTA
$2.25B
| $13.5M | 2.97% | 1,030,000 -395,000 | -28% | -$5.19M |
|
18
Pharvaris
PHVS
$1.39B
| $11.8M | 2.6% | 672,595 -97,220 | -13% | -$1.71M |
|
|
19
Kymera Therapeutics
KYMR
$2.95B
| $11.6M | 2.55% | +266,000 | New | +$11.6M |
|
|
ABVX
20
Abivax
ABVX
$6.12B
| $9.69M | 2.13% | 1,267,000 +37,000 | +3% | +$283K |
|
|
DBVT
21
DBV Technologies
DBVT
$264M
| $9.31M | 2.04% | +1,018,021 | New | +$9.31M |
|
22
Corbus Pharmaceuticals
CRBP
$115M
| $7.69M | 1.69% | 1,115,000 | – | – |
|
23
MoonLake Immunotherapeutics
MLTX
$3.54B
| $6.99M | 1.53% | 148,000 -148,000 | -50% | -$6.99M |
|
24
Unicycive Therapeutics
UNCY
$74M
| $4.77M | 1.05% | 1,000,000 -9,000,000 | -90% | -$42.9M |
|
25
Neurogene
NGNE
$264M
| $4.53M | 0.99% | 303,000 | – | – |
|